A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Children's Hospital of Philadelphia
Fundación de investigación HM
Beijing Biotech
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Australian & New Zealand Children's Haematology/Oncology Group
University of Alabama at Birmingham
Blueprint Medicines Corporation
Memorial Sloan Kettering Cancer Center
Universitair Ziekenhuis Brussel
Université de Sherbrooke
Regeneron Pharmaceuticals
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Haukeland University Hospital
Bayer
Eisai Inc.
City of Hope Medical Center
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Boston Scientific Corporation
Proximagen, LLC
Southwest Hospital, China
National University Hospital, Singapore
Ohio State University Comprehensive Cancer Center
Novartis
Novartis
Hadassah Medical Organization
INSYS Therapeutics Inc
INSYS Therapeutics Inc
Myrexis Inc.
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center